Drug Trial Radar · NCT07551492
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9,262
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
May 24, 2031
Study completion Jun 28, 2031
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
HRS9531Drug
HRS9531 Dose 1 , subcutaneous injection
HRS9531 placeboDrug
HRS9531 placebo Dose 1, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time from randomization to the first occurrence of the MACE-3 composite endpointTime frame: approximately up to 61 months of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital, CAMS&PUMC
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.